Carregando...
The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitis
BACKGROUND: CT‐P13, a biosimilar of the reference product infliximab, has been approved for the treatment of ulcerative colitis on the basis of the results of trials conducted in patients with spondyloarthritis and rheumatoid arthritis. AIM: To compare the effectiveness and safety of CT‐P13 and the...
Na minha lista:
| Publicado no: | Aliment Pharmacol Ther |
|---|---|
| Principais autores: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6767082/ https://ncbi.nlm.nih.gov/pubmed/31115919 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15323 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|